<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Arbutus Biopharma Corp — News on 6ix</title>
    <link>https://6ix.com/company/arbutus-biopharma-corp</link>
    <description>Latest news and press releases for Arbutus Biopharma Corp on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 15 Apr 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/arbutus-biopharma-corp" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835418b78dffbe2df0e0e6e.webp</url>
      <title>Arbutus Biopharma Corp</title>
      <link>https://6ix.com/company/arbutus-biopharma-corp</link>
    </image>
    <item>
      <title>Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B</title>
      <link>https://6ix.com/company/arbutus-biopharma-corp/news/arbutus-receives-us-fda-fast-track-designation-for-imdusiran-for-the-treatment-of-chronic-hepatitis-b</link>
      <guid isPermaLink="true">https://6ix.com/company/arbutus-biopharma-corp/news/arbutus-receives-us-fda-fast-track-designation-for-imdusiran-for-the-treatment-of-chronic-hepatitis-b</guid>
      <pubDate>Wed, 15 Apr 2026 04:00:00 GMT</pubDate>
      <description>Fast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran WARMINSTER, Pa., April 15, 2026 (GLOBE NEWSWIRE) --</description>
    </item>
    <item>
      <title>Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/arbutus-biopharma-corp/news/arbutus-reports-fourth-quarter-and-year-end-2025-financial-results-and-provides-corporate-update</link>
      <guid isPermaLink="true">https://6ix.com/company/arbutus-biopharma-corp/news/arbutus-reports-fourth-quarter-and-year-end-2025-financial-results-and-provides-corporate-update</guid>
      <pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
      <description>Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of December 2025 $2.25B Moderna global settlement for</description>
    </item>
    <item>
      <title>Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna</title>
      <link>https://6ix.com/company/arbutus-biopharma-corp/news/genevant-sciences-and-arbutus-biopharma-announce-dollar225-billion-global-settlement-with-moderna</link>
      <guid isPermaLink="true">https://6ix.com/company/arbutus-biopharma-corp/news/genevant-sciences-and-arbutus-biopharma-announce-dollar225-billion-global-settlement-with-moderna</guid>
      <pubDate>Tue, 03 Mar 2026 21:15:00 GMT</pubDate>
      <description>Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appealIf the $1.3 billion payment is realized, this settlement will be the largest disclosed patent settlement paid in the pharmaceutical industry and the second largest in any industrySettlement holds Moderna accountable for infringement and provides for the court to enter judgment of no invalidity on the four Genevant/Arbutus patents asserted</description>
    </item>
    <item>
      <title>Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/arbutus-biopharma-corp/news/arbutus-reports-third-quarter-2025-financial-results-and-provides-corporate-update</link>
      <guid isPermaLink="true">https://6ix.com/company/arbutus-biopharma-corp/news/arbutus-reports-third-quarter-2025-financial-results-and-provides-corporate-update</guid>
      <pubDate>Thu, 13 Nov 2025 05:00:00 GMT</pubDate>
      <description>Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March 2026;Favorable</description>
    </item>
    <item>
      <title>Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025</title>
      <link>https://6ix.com/company/arbutus-biopharma-corp/news/arbutus-announces-four-abstracts-accepted-presentation-aasld-liver-meetingr-2025-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/arbutus-biopharma-corp/news/arbutus-announces-four-abstracts-accepted-presentation-aasld-liver-meetingr-2025-2025</guid>
      <pubDate>Tue, 07 Oct 2025 04:00:00 GMT</pubDate>
      <description>Multiple abstracts accepted featuring imdusiran clinical data – highlighting progress toward a potential functional cure for chronic hepatitis B virus AB-101</description>
    </item>
    <item>
      <title>Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/arbutus-biopharma-corp/news/arbutus-reports-second-quarter-2025-financial-results-and-provides-corporate-update</link>
      <guid isPermaLink="true">https://6ix.com/company/arbutus-biopharma-corp/news/arbutus-reports-second-quarter-2025-financial-results-and-provides-corporate-update</guid>
      <pubDate>Wed, 06 Aug 2025 04:00:00 GMT</pubDate>
      <description>Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran Dr. Roger Sawhney joins the</description>
    </item>
    <item>
      <title>Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus</title>
      <link>https://6ix.com/company/arbutus-biopharma-corp/news/arbutus-reacquires-greater-china-rights-imdusiran-and-announces-scientific-advisory</link>
      <guid isPermaLink="true">https://6ix.com/company/arbutus-biopharma-corp/news/arbutus-reacquires-greater-china-rights-imdusiran-and-announces-scientific-advisory</guid>
      <pubDate>Wed, 25 Jun 2025 04:00:00 GMT</pubDate>
      <description>Qilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Greater China Drs. Jordan Feld, Ed Gane, Anna Lok, Mark</description>
    </item>
    <item>
      <title>Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/arbutus-biopharma-corp/news/arbutus-reports-first-quarter-2025-financial-results-and-provides-corporate-update</link>
      <guid isPermaLink="true">https://6ix.com/company/arbutus-biopharma-corp/news/arbutus-reports-first-quarter-2025-financial-results-and-provides-corporate-update</guid>
      <pubDate>Wed, 14 May 2025 04:00:00 GMT</pubDate>
      <description>Imdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B (cHBV) to date, including 2 patients who received no interferon</description>
    </item>
    <item>
      <title>Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025</title>
      <link>https://6ix.com/company/arbutus-biopharma-corp/news/arbutus-presents-clinical-trial-data-its-two-hbv-assets-imdusiran-and-ab-101-european</link>
      <guid isPermaLink="true">https://6ix.com/company/arbutus-biopharma-corp/news/arbutus-presents-clinical-trial-data-its-two-hbv-assets-imdusiran-and-ab-101-european</guid>
      <pubDate>Wed, 07 May 2025 04:00:00 GMT</pubDate>
      <description>Data highlighted in late-breaker poster presentation shows that imdusiran achieves functional cure in chronic hepatitis B (cHBV) patients when combined with</description>
    </item>
    <item>
      <title>Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025</title>
      <link>https://6ix.com/company/arbutus-biopharma-corp/news/arbutus-present-imdusiran-and-ab-101-data-easl-congress-2025-2025-04-23</link>
      <guid isPermaLink="true">https://6ix.com/company/arbutus-biopharma-corp/news/arbutus-present-imdusiran-and-ab-101-data-easl-congress-2025-2025-04-23</guid>
      <pubDate>Wed, 23 Apr 2025 04:00:00 GMT</pubDate>
      <description>Five abstracts accepted for poster presentations WARMINSTER, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus”</description>
    </item>
    <item>
      <title>Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/arbutus-biopharma-corp/news/arbutus-reports-fourth-quarter-and-year-end-2024-financial-results-and-provides</link>
      <guid isPermaLink="true">https://6ix.com/company/arbutus-biopharma-corp/news/arbutus-reports-fourth-quarter-and-year-end-2024-financial-results-and-provides</guid>
      <pubDate>Thu, 27 Mar 2025 04:00:00 GMT</pubDate>
      <description>Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S. mRNA-LNP</description>
    </item>
    <item>
      <title>Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna</title>
      <link>https://6ix.com/company/arbutus-biopharma-corp/news/genevant-sciences-and-arbutus-biopharma-initiate-international-patent-infringement</link>
      <guid isPermaLink="true">https://6ix.com/company/arbutus-biopharma-corp/news/genevant-sciences-and-arbutus-biopharma-initiate-international-patent-infringement</guid>
      <pubDate>Mon, 03 Mar 2025 05:00:00 GMT</pubDate>
      <description>BASEL, Switzerland and VANCOUVER, B.C. and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with</description>
    </item>
    <item>
      <title>Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO</title>
      <link>https://6ix.com/company/arbutus-biopharma-corp/news/arbutus-announces-changes-board-directors-120000132</link>
      <guid isPermaLink="true">https://6ix.com/company/arbutus-biopharma-corp/news/arbutus-announces-changes-board-directors-120000132</guid>
      <pubDate>Tue, 25 Feb 2025 12:00:00 GMT</pubDate>
      <description>WARMINSTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced changes to its board of directors and the appointment of Lindsay Androski, J.D., M.B.A., as Chief Executive Officer. Ms. Androski replaces Michael J. McElhaugh, the Company’s Interim President and CEO, effective immediately. Ms. Androski will also serve as a member of the Company’s b</description>
    </item>
    <item>
      <title>Arbutus Provides 2025 Corporate and Financial Update</title>
      <link>https://6ix.com/company/arbutus-biopharma-corp/news/arbutus-provides-2025-corporate-and-financial-update-2025-01-13</link>
      <guid isPermaLink="true">https://6ix.com/company/arbutus-biopharma-corp/news/arbutus-provides-2025-corporate-and-financial-update-2025-01-13</guid>
      <pubDate>Mon, 13 Jan 2025 05:00:00 GMT</pubDate>
      <description>Initiating Phase 2b clinical trial in first half of 2025 after achieving a meaningful functional cure rate in cHBV patients treated with imdusiran and</description>
    </item>
    <item>
      <title>Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat</title>
      <link>https://6ix.com/company/arbutus-biopharma-corp/news/arbutus-participate-hc-wainwright-home-virtual-fireside-chat-2024-11-26</link>
      <guid isPermaLink="true">https://6ix.com/company/arbutus-biopharma-corp/news/arbutus-participate-hc-wainwright-home-virtual-fireside-chat-2024-11-26</guid>
      <pubDate>Tue, 26 Nov 2024 05:00:00 GMT</pubDate>
      <description>WARMINSTER, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage</description>
    </item>
    <item>
      <title>Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon</title>
      <link>https://6ix.com/company/arbutus-biopharma-corp/news/arbutus-imdusiran-achieves-functional-cure-chbv-patients-when-combined-short-course</link>
      <guid isPermaLink="true">https://6ix.com/company/arbutus-biopharma-corp/news/arbutus-imdusiran-achieves-functional-cure-chbv-patients-when-combined-short-course</guid>
      <pubDate>Fri, 15 Nov 2024 05:00:00 GMT</pubDate>
      <description>50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial Overall, in</description>
    </item>
    <item>
      <title>Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B</title>
      <link>https://6ix.com/company/arbutus-biopharma-corp/news/arbutus-and-barinthus-bio-announce-new-data-im-prove-ii-trial-showing-addition-0</link>
      <guid isPermaLink="true">https://6ix.com/company/arbutus-biopharma-corp/news/arbutus-and-barinthus-bio-announce-new-data-im-prove-ii-trial-showing-addition-0</guid>
      <pubDate>Fri, 15 Nov 2024 05:00:00 GMT</pubDate>
      <description>Significantly greater mean declines in HBsAg levels</description>
    </item>
    <item>
      <title>Arbutus to Present at Jefferies London Healthcare Conference</title>
      <link>https://6ix.com/company/arbutus-biopharma-corp/news/arbutus-present-jefferies-london-healthcare-conference-2024-11-14</link>
      <guid isPermaLink="true">https://6ix.com/company/arbutus-biopharma-corp/news/arbutus-present-jefferies-london-healthcare-conference-2024-11-14</guid>
      <pubDate>Thu, 14 Nov 2024 05:00:00 GMT</pubDate>
      <description>WARMINSTER, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage</description>
    </item>
    <item>
      <title>Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/arbutus-biopharma-corp/news/arbutus-reports-third-quarter-2024-financial-results-and-provides-corporate-update</link>
      <guid isPermaLink="true">https://6ix.com/company/arbutus-biopharma-corp/news/arbutus-reports-third-quarter-2024-financial-results-and-provides-corporate-update</guid>
      <pubDate>Wed, 06 Nov 2024 05:00:00 GMT</pubDate>
      <description>Imdusiran data from IM-PROVE I and IM-PROVE II Phase 2a clinical trials to be presented at upcoming AASLD - The Liver Meeting 2024 Multiple-ascending doses of</description>
    </item>
    <item>
      <title>Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update</title>
      <link>https://6ix.com/company/arbutus-biopharma-corp/news/arbutus-report-third-quarter-2024-financial-results-and-provide-corporate-update-2024</link>
      <guid isPermaLink="true">https://6ix.com/company/arbutus-biopharma-corp/news/arbutus-report-third-quarter-2024-financial-results-and-provide-corporate-update-2024</guid>
      <pubDate>Wed, 23 Oct 2024 04:00:00 GMT</pubDate>
      <description>WARMINSTER, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”) a clinical-stage</description>
    </item>
  </channel>
</rss>